GlobeNewswire by notified

Basilea shareholders approve all proposals of the board of directors at the annual general meeting

Share

Press Release

Basel, Switzerland, April 13, 2022

Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM) for the financial year 2021.

In accordance with the COVID-19 Ordinance 3 issued by the Swiss Federal Council, the board of directors of Basilea Pharmaceutica Ltd. had decided to hold the AGM 2022 without the physical presence of shareholders. Accordingly, shareholders exercised their voting rights exclusively via the independent proxy. At the AGM, a total of 3,759,995 shareholder votes, equivalent to 28.9% of the share capital and 49.1% of the shares entitled to vote, were represented by the independent proxy.

At the AGM, the shareholders approved the annual report, the financial statements and the consolidated financial statements for the financial year 2021. They also endorsed carrying forward the accumulated deficit and approved the discharge of the members of the Board of Directors and the Management Committee.

Domenico Scala was re-elected as Chairman and Dr. Martin Nicklasson, Dr. Nicole Onetto, Steven D. Skolsky and Dr. Thomas Werner were re-elected as members of the Board of Directors. Leonard Kruimer was elected as new member of the Board. Following the election at the AGM, the Board appointed him as the Chairman of the Audit Committee. In addition, Dr. Nicklasson, Dr. Onetto and Dr. Werner were re-elected to the Compensation Committee. The term of all board members lasts until the AGM 2023.

The shareholders also approved the proposed maximum aggregate amount of compensation for the Board of Directors for the period to the AGM 2023, and the maximum aggregate amount of compensation for the Management Committee for the financial year 2023. In a non-binding advisory vote, the shareholders endorsed the compensation report for the financial year 2021.

The shareholders approved the proposed amendment of the Articles of Association to create additional conditional share capital.

Moreover, the shareholders approved the amendment of the Articles of Association to change Basilea’s registered office following the move of headquarters. Finally, they also re-elected Dr. Caroline Cron as independent proxy until the end of the next AGM and re-elected PricewaterhouseCoopers Ltd, Basel, as auditors for the financial year 2022.

At the time of the AGM, 66.2% of the share capital were registered in Basilea’s share register.

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with bacterial and fungal infections and cancer. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. We are conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have several preclinical assets in both anti-infectives and cancer in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations
Phone +41 61 606 1102
E-mail media_relations@basilea.com
investor_relations@basilea.com

This press release can be downloaded from www.basilea.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Cool Company Ltd. – Q1 2022 Business Update call16.5.2022 23:04:27 CEST | Press release

Cool Company Ltd will hold a Q1 2022 business update call for investors at 10am Oslo time on Tuesday May 31. Prior to the start of the call a presentation will be made available in the Investors section of the Cool Company Ltd. website www.coolcoltd.com We recommend that participants join the conference call via the listen-only live webcast link provided. Sell-side analysts interested in raising a question during the Q&A session that will immediately follow the presentation should access the event via the conference call dial-in information below. Please dial in 10 minutes prior to the start time to allow time for call handling. Information on how to ask questions will be given at the beginning of the Q&A session. There will be a limit of two questions per participant. a. Listen-only live webcastlink Go to the Investors section at www.coolcoltd.com and click on the link to "Webcast". To listen to the conference call from the web, you need to have installed Windows Media Player, and you

Golar releases its 2021 Environmental, Social and Governance report16.5.2022 22:53:05 CEST | Press release

Golar LNG Limited (“Golar”) is pleased to announce that it has issued its 2021 Environmental, Social and Governance (“ESG”) report. This comprehensive report describes Golar’s important role in advancing the global energy transition to a lower carbon future - championing LNG as a transition fuel in partnership with renewables, and as a reliable alternative for those in need of energy security today. As part of our target to further reduce emissions from our operations Golar has invested in a carbon capture technology company that has developed and achieved proof of concept for a CO2 capture and separation membrane technology. Subject to successful completion of a commercial pilot project with another industrial user, the technology could be used in future FLNG projects. Our 2021 ESG report is attached and will also be posted to our website. Forward-Looking Statements This press release contains forward-looking statements (as defined in Section 21E of the Securities Exchange Act of 1934

Inventiva reports 2022 First Quarter Financial Information and provides clinical development update16.5.2022 22:00:00 CEST | Press release

Cash position2 at €80.5m as of March 31, 2022The Group did not generate any revenue in Q1 2022Signature of a €50 million bullet credit facility agreement with the European Investment BankUpdate on lanifibranor recruitment timing for Phase III trial in patients with NASH, as well as for the two Phase II trials in patients with NAFLD and type 2 diabetes, and in combination with empagliflozine Daix (France), Long Island City (New York, United States), May 16, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today reported its cash position as of March 31, 2022 and its revenues for the first quarter of 20221, and provided an update on its clinical programs. Cash Position As of March 31, 2022, Inventiva’s cash position stood at €80.5 million com

ASM INTERNATIONAL N.V. ANNOUNCES VOTING RESULTS OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS16.5.2022 21:00:00 CEST | Press release

Almere, the Netherlands May 16, 2022 ASM International N.V. (Euronext Amsterdam: ASM) today announces the voting results of its Annual General Meeting of Shareholders held on May 16, 2022, at the Van der Valk Hotel in Almere, the Netherlands. The shareholders approved all resolutions as proposed to the Annual General Meeting of Shareholders. The main approved resolutions include the following: Mr. Hichem M’Saad was appointed as a member of the Management Board and as the CTO. The Remuneration Policy for the Management Board and for the Supervisory Board were approved. Also Mr. Marc de Jong was reappointed as member of the Supervisory Board. Furthermore the financial statements for the year 2021 were adopted, the shareholders discharged the members of the Management Board and Supervisory Board from liability in relation to the exercise of their duties in the financial year 2021, and the shareholders also voted in favor of a regular dividend payment of €2.50 per common share. About ASM I

Electra Gruppen AB (publ) (u.ä.t Elon AB (publ)) offentliggör prospekt avseende upptagande till handel av nyemitterade aktier på Nasdaq Stockholm i samband med apportemission16.5.2022 18:00:00 CEST | Pressemelding

ELECTRA GRUPPEN AB (publ) orgnr. 556065-4054 Pressmeddelande 2022-05-16 Electra Gruppen AB (publ) (u.ä.t Elon AB (publ)) offentliggör prospekt avseende upptagande till handel av nyemitterade aktier på Nasdaq Stockholm i samband med apportemission Electra Gruppen AB (publ) (u.ä.t Elon AB (publ)) (”Electra” eller ”Bolaget”), offentliggör idag det prospekt som upprättats inför upptagande till handel av de nyemitterade aktierna på Nasdaq Stockholm med anledning av den apportemission genom vilken Electra förvärvar samtliga aktier i Elon Group AB (”Elon”) (”Transaktionen”). Transaktionen beskrivs närmare i Electras pressmeddelande daterat den 7 december 2021. På Electras årsstämma den 28 mars 2022 bemyndigades styrelsen att besluta om apportemissionen för att genomföra Transaktionen. Den 13 maj 2022 beslutade Electras styrelse om apportemission av 9 659 223 aktier till Elon Group Holding. Prospektet som har upprättats med anledning av upptagande till handel av de nyemitterade aktierna i samb